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Abstract
Background: Common fragile sites (cfs) are specific regions in the human genome that are particularly
prone to genomic instability under conditions of replicative stress. Several investigations support the view
that common fragile sites play a role in carcinogenesis. We discuss a genome-wide approach based on
graph theory and Gene Ontology vocabulary for the functional characterization of common fragile sites
and for the identification of genes that contribute to tumour cell biology.
Results: Common fragile sites were assembled in a network based on a simple measure of correlation
among common fragile site patterns of expression. By applying robust measurements to capture in
quantitative terms the non triviality of the network, we identified several topological features clearly
indicating departure from the Erdos-Renyi random graph model. The most important outcome was the
presence of an unexpected large connected component far below the percolation threshold. Most of the
best characterized common fragile sites belonged to this connected component. By filtering this connected
component with Gene Ontology, statistically significant shared functional features were detected.
Common fragile sites were found to be enriched for genes associated to the immune response and to
mechanisms involved in tumour progression such as extracellular space remodeling and angiogenesis.
Moreover we showed how the internal organization of the graph in communities and even in very simple
subgraphs can be a starting point for the identification of new factors of instability at common fragile sites.
Conclusion: We developed a computational method addressing the fundamental issue of studying the
functional content of common fragile sites. Our analysis integrated two different approaches. First, data
on common fragile site expression were analyzed in a complex networks framework. Second, outcomes
of the network statistical description served as sources for the functional annotation of genes at common
fragile sites by means of the Gene Ontology vocabulary. Our results support the hypothesis that fragile
sites serve a function; we propose that fragility is linked to a coordinated regulation of fragile genes
expression.
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Fragile sites are hot spots more sensitive to sister chroma-
tid exchange and recombination, plasmid and DNA viral
integration and amplicons than other regions of the
human genome.
Fragile sites are thought as an inherent component of
chromosomal structure. These sites can extend over large
DNA sequences, often up to several Mbp in length. They
are said to be 'expressed' when they exhibit cytogenetic
abnormalities that appear as gaps or breaks on metaphase
chromosomes. Fragile site expression can be elicited by
treatment of cells with aphidicolin that inhibits DNA
polymerases α and δ. At present 84 common fragile sites
(75 out of them are aphidicolin-inducible) are listed in
the genome database GDB [37]. The exact number of
common fragile sites is a matter of interpretation because
increasing the stress placed on DNA replication leads to
the expression of an increasing number of fragile sites.
Fragile site susceptibility to even low doses of replication
inhibitors suggests that they are regions intrinsically diffi-
cult to replicate [1].
Molecular sequence analyses reveal no intrinsic character-
istics of these regions that might explain their instability
[2]. However, these unstable regions are evolutionarily
conserved; this suggests that they may have a functional
role [3]. Up to now sequencing shows the presence of AT-
rich regions characterized by high flexibility [4] and low
stability but they do not seem sufficient by themselves to
explain fragility.
More progress has been made in the identification of fac-
tors acting in trans to regulate fragile site expression.
Indeed fragile site stability is thought to be ensured by
chromosome-bound signal transduction proteins that
mediate checkpoint responses during cell cycle.
Such a hypothesis is supported by several pieces of evi-
dence. In particular, a few papers demonstrate that ATR
activity may protect fragile sites from their expression pro-
posing different models [5-8].
Over the past few years common fragile sites have become
an important issue in cancer biology. Indeed the require-
ment of several mutations for tumorigenesis and the fact
that most cancers harbour a large number of genetic and/
or epigenetic changes have led to suggestions that fragile
site-associated instability is a hallmark of tumorigenesis.
Several studies demonstrate that at FRA3B and FRA16D
(the most expressed fragile sites) large, intra-locus dele-
tions or translocations often alter genes such as FHIT and
WWOX [9]. Both genes show tumour suppressor func-
tions. In addition, fragile sites initiate breakage-fusion-
bridge (BFB) cycles responsible for gene amplification.
Amplicons, which partially map to FRA7G and involve
the MET oncogene, have been recently found in six pri-
mary esophageal adenocarcinomas [10]. These findings
strongly corroborate the hypothesis that altered genetic
expression due to rearrangements at fragile sites could
have a causal role in cancer.
However recent reports challenge the prevailing view ask-
ing whether, given that common fragile sites are a normal
component of human chromosomes, they can play a pro-
tective role against cancer at the incipient tumour stages.
Experimental evidences show that tumorigenic events
activate the ATR/ATM-regulated checkpoint through
deregulated DNA replication and DNA damage and
thereby activate an inducible barrier against tumour pro-
gression [11,12]. Fragile site-associated instability could
take part to the cellular counter-response against onco-
genic stress.
The above evidences suggest two possible scenarios: frag-
ile sites can promote tumour progression or can act as
'sensors' to elicit, by altered expression of their genes, cel-
lular response against hazards at preliminary stages. One
of the aims of our work is to shed some light on this issue
by looking at the common functions of genes located at
fragile sites which show correlated expression patterns.
Most of the studies on fragile sites since their discovery
were based on a site-by-site approach. In this paper we try
to reconsider this modeling paradigm and ask whether
our understanding of fragile sites might benefit from a
comparative description. In our opinion the tools elabo-
rated in the last years in the context of complex networks
theory offer the ideal framework to try a description of
fragile sites as an interconnected system.
We are motivated by the observation of a correlation
between breakage levels at two very frequent fragile sites
(FRA3B and FRA16D) and at a number of less frequent
other ones in lymphocytes from subjects exposed to radi-
ation and affected by radiation-induced thyroid cancer
reported in [13]. The cells from the subjects showing the
highest fragility were also characterized by a reduced abil-
ity to undergo apoptosis, which is a well-known function
of the fragile genes FHIT and WWOX, mapping to FRA3B
and FRA16D respectively. These findings suggest that
genes located at fragile sites share functions that could be
involved in a common biological process and that fragil-
ity at fragile sites, by altering genetic expression, could
somehow bias such process.
The simplest and most effective measure to assemble frag-
ile sites in a relational network is the correlation of their
expression profiles on a controlled sample. We apply
robust tools and measurements to capture in quantitativePage 2 of 18
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encoded in its topology.
We then suggest that the theoretical efforts mentioned
above serve as a driving source to uncover the functional
properties of fragile sites. We think that if the topology of
the co-expression network indeed deviates from a random
graph it should somehow correspond to a coordination
among factors of instability placed at fragile sites. To clar-
ify functional implications of the topological analysis out-
comes we filter highly significant substructures (to be
defined below) by means of the Gene Ontology (GO)
functional annotation scheme [14].
Gene Ontology provides a dynamic, controlled vocabu-
lary for describing gene products in any organism. GO
includes three extensive subontologies describing molec-
ular function (the biochemical activity of a gene product),
biological process (the biological goal a gene product con-
tributes to) and cellular component (the cellular place
where the biological activity of a gene product is exerted).
Each term has an accession number, a name, a more
detailed definition and other information relating this
term to its parent terms. Individual terms are organized as
a directed acyclic graph, in which the terms form the
nodes in the ontology and the links the relationships.
Descendent terms are related to their parent terms by 'is-
a' relationships or 'part-of' relationships. In contrast to
simpler hierarchical structures, one node in a directed acy-
clic graph may have multiple parents. This allows for a
more flexible and detailed description of biological func-
tions. The GO terms do not themselves describe specific
genes or gene products; instead, collaborating databases
generate associations of GO terms to specific gene prod-
ucts. Gene products are annotated at the most specific
level possible, but are considered to share the attributes of
all ancestor terms.
Results and discussion
Graph theoretical analysis allows to identify strictly 
interrelated fragile sites
Our starting point is the set of 116 significantly expressed
fragile sites selected as discussed in details in the Methods
section. Fragile site definition is a matter of interpretation
based on criteria for inclusion and statistical analysis of
data. To detect non-random breakpoints we adopt the
approach described in [15] under the proportional prob-
ability (PPM) assumption (the probability of a random
break at a region is proportional to the region width). In
this paper the authors suggest an iterative procedure that
recognizes fragile sites using highest observed breakages.
Interestingly 68 out of our 116 fragile sites selected in this
way are annotated as aphidicolin-sensitive common frag-
ile sites at the NCBI database [37].
We then evaluate the Spearman's rank-order correlation
coefficient between the expression patterns of each pair of
fragile sites (see again the Methods section for definitions)
and we select only those pairs with a correlation higher
than a given threshold.
More precisely we set three thresholds:
rs = 0.562. This threshold corresponds to correlators
which have only a (Bonferroni corrected) probability of
1% to appear by chance. This choice allows us to pick up
only highly correlated pairs of fragile sites.
rs = 0.527. This choice allows us to select all pairs of fragile
sites showing a relevant degree of correlation (only 5% of
Bonferroni corrected probability to be selected by
chance).
rs = 0.511. This choice allows us to select all pairs of fragile
sites showing a significant correlation (10% of Bonferroni
corrected probability to be selected by chance).
Let us examine our findings in these three cases in detail.
At each significance level connected components are
named by capital letters. If, by reducing the stringency of
significance for fragile site correlation, some connected
components merge into a new enlarged one then the label
of this last one includes multiple letters, one for each
merged connected component. In the following discus-
sion of features related to connected components, we
always specify the significance level at which we refer in
the label of the connected components themselves.
First threshold
Highly correlated sites (rs ≥ 0.562). 46 correlation coeffi-
cients, out of the possible 6670, survive this selection. The
fragile sites linked by these correlators turn out to be
organized in a main connected component (A1) including
18 nodes joined by 40 links.
Remaining nodes are organized in an isolated link (C1)
and in a set of 6 nodes joined by 5 links (B1). A visualiza-
tion of the whole network is reported in Figure 1.
Fragile sites, organized as just described, are listed in Tab
1.
Second threshold
(rs ≥ 0.527). Above this threshold 63 correlation coeffi-
cients survive.
The majority of these correlators (57 out of 63) collapse
again in a main connected component (A5) composed by
21 vertices. Besides this large component, the other 2 sub-
graphs (B5, C5) are still present. A full list of correlatedPage 3 of 18
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is reported in Figure 2.
Third threshold
(rs ≥ 0.511). At this threshold 84 correlation coefficients
exist among 33 fragile sites. The most evident change con-
cerns the main connected component which absorbs both
the set made of 6 nodes and the single link mentioned at
the upper thresholds (ABC10). The main connected com-
ponent increases its size up to 31 nodes and involves a
total of 83 links. Besides this feature, only a single link
appears (D10). A full list of correlated fragile sites at this
threshold can be found again in Tab 1. The network is
reported in Figure 3.
It is important to stress that the presence of a large con-
nected component (the one with 18 vertices) at the high-
est threshold is a highly non trivial and unexpected result.
This is best appreciated by comparing our finding with
what we would expect for a standard Erdos-Renyi random
graph with the same number of links.
The highest threshold discussed above corresponds to a
link density p = 0.0069 i.e. to a mean expected degree z =
0.79 which is far below the percolation threshold (which
is located at z = 1 for this class of graphs). This observation
suggests that the above connected component is definitely
non-random and should contain some kind of biological
information. We shall deal with the problem of extracting
this information in the next section.
In order to evaluate in a more quantitative way the fea-
tures of the networks that we find and also to measure the
importance of the nodes in the network we used three
Table 1: Clustered fragile sites as they are detected by means of the Hoshen-Kopelman algorithm at the three significance thresholds 
(see text).
Thresh
old
Cluster Nodes Links Fragile sites
1% A1 18 40 FRA1C FRA1D FRA1E FRA1G FRA2D FRA2H FRA3C FRA5E FRA6E FRA7G
FRA9C FRA11D FRA13A FRA18A FRA20B FRA22B FRAXB FRAXC
B1 6 5 FRA3B FRA7F FRA7H FRA14C FRA16C FRA16D
C1 2 1 14q21 18p11
5% A5 21 57 FRA1C FRA1D FRA1E FRA1G FRA2D FRA2H FRA3C FRA5D FRA5E FRA6E
7p14 FRA7G FRA9C FRA10F FRA11D FRA13A FRA18A FRA20B FRA22B FRAXB
FRAXC
B5 6 5 FRA3B FRA7F FRA7H FRA14C FRA16C FRA16D
C5 2 1 14q21 18p11
10% ABC10 31 83 FRA1C FRA1D FRA1E FRA1G 1q43 FRA2D FRA2H FRA3B FRA3C FRA5D
FRA5E FRA6E 7p14 FRA7B FRA7F FRA7G FRA7H FRA9C FRA10F FRA11D
FRA13A FRA14C 14q21 FRA16C FRA16D 18p11 FRA18A FRA20B FRA22B FRAXB
FRAXC
D10 2 1 FRA5C 7p15
Capital letters label connected components at each significance level α that is reported in the left-most column. Labels including multiple letters 
reflect connected components merging. Numbers in labels indicate the significance level at which connected components are detected. The third 
and fourth columns include respectively the number of fragile sites and of internal links for each connected component. Fragile sites are reported in 
the right-most column.
Visualization of the network based on correlated expression patterns f r fragil  sites at α = 1%F gu e 1
Visualization of the network based on correlated expression 
patterns for fragile sites at α = 1%.
FRA1C FRA1E
FRA2H
FRA3C
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FRA7G
FRA11D
FRA13A
FRA18A
FRA20B
FRA22B FRAXB
FRA1D
FRA1G
FRA2D
FRA9C
FRA3BFRA16C FRA16D
FRA6E
FRA7F FRA7H
FRAXC
FRA14C
14q21 18p11Page 4 of 18
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oretical analysis of networks: degree, betweenness and
clustering coefficient.
Degree
The simplest measure is degree, which is the number of
links connected to a vertex in a network. The probability
of finding a vertex of degree k in a Erdos-Renyi random
graph is given by a Poisson distribution (see Methods sec-
tion). We see that, looking for instance at the highest
threshold network, the probability of having a vertex of
degree 2 is 0.14 while (what is more impressive) the prob-
ability of having a vertex of degree 11 is 8.50e-10. This is
the case for instance of FRA22B. It is interesting to observe
that even at lower thresholds the connectivity degree of
FRA22B remains remarkably high with respect to the ran-
dom graph expected probability: at the intermediate
threshold the degree of FRA22B becomes 13 (probability
1.48e-10) while at the lowest threshold its connectivity
becomes 14 (probability 4.89e-10). Besides FRA22B, the
number of fragile sites exhibiting degree higher than 2 in
the three networks is in any case very high and increases
from 13 at α = 1% to 15 at α = 5% and finally to 19 at α =
10%. Data are available in Tab 2.
Betweenness
A more sophisticated centrality measure is betweenness.
Betweenness is a measure of the extent to which a node
lies on the paths between others. We define the between-
ness of a node i as the fraction of shortest paths between
pairs of nodes in the network that pass through i. Values
are reported in Tab 3.
Clustering
An even more useful tool to identify non random features
in biological networks is the property of clustering (some-
times also called network transitivity). It can be measured
using the clustering coefficient C. It is essentially the mean
probability that two vertices that are network neighbours
of the same other vertex are also neighbours. We calculate
the clustering coefficient for the whole network. In an
Erdos-Renyi random graph C can be easily evaluated and
coincides with p (the link density) whose value is very
small in all the three graphs. On the contrary in our graphs
the clustering coefficient has remarkably high values, with
a ratio between the values that we find and the Erdos-
Renyi ones higher than 30 (see Tab 4).
This strong tendency of the expressed and correlated frag-
ile sites to cluster among them suggested us to perform a
community analysis of the connected components in all
three networks.
Community analysis
Roughly speaking communities are groups of vertices
within a connected cluster which have a high density of
edges within them and a lower density of edges with other
communities. There are by now several algorithmic tools
which allow to reconstruct the community structure of a
given graph (see Methods section for a discussion of one
we used); the quality of the community reconstruction is
usually given by the so called "modularity coefficient" Q
(see Methods section). The rather high values of the clus-
tering coefficient and of the betweenness (which are usu-
ally indicators of a potential good community
organization) prompted us to perform a community anal-
ysis for our networks.
Visualization of the network based on correlated expression patterns f r fragil  sites at α = 10%F gu e 3
Visualization of the network based on correlated expression 
patterns for fragile sites at α = 10%.
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Visualization of the network based on correlated expression patterns f r fragil  sites at α = 5%F gu e 2
Visualization of the network based on correlated expression 
patterns for fragile sites at α = 5%.
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very clearly divided into two communities which coincide
almost exactly with the connected components that we
observe at higher levels of the threshold.
In turn these connected components are at this point very
well defined and show no evidence of further organiza-
tion in subcommunities. Indeed they keep their identity
even if we enhance the stringency level up to α = 1% (see
Tab 5). Remarkably enough this clean separation in com-
munities is also reflected in a sharp separation at the level
of GO annotations, a fact which will play a major role in
the following discussion. These findings confirm the gen-
eral impression that the network organization of most
common fragile sites is biologically relevant and support
the hypothesis that fragile sites serve a function. We shall
make use of all these results in the functional analysis of
the next section.
Functional characterization of connected components by 
Gene Ontology tool
Once equipped with the described network of fragile sites,
our further goal is to find out functional relationships
among sites forming the network, which up to now have
been thought to be functionally independent.
At each significance level the network based on correlated
expression patterns is characterized by a non trivial inner
organization. Two stable connected components are
detected at α = 1% and α = 5%. At α = 10% they are still
recognizable as different communities albeit they merge
in a unique connected component.
Our aim at this point is to understand if this network
structure observed among fragile sites implies some kind
of functional interaction among the genes which are con-
tained in such fragile sites.
Table 2: Deviations of fragile sites' degrees in the correlation-based network from the Erdos-Renyi random model.
α Degree Erdos-Renyi 
p-value
Fragile sites
1% 11 8.50e-10 FRA1C FRA22B
9 1.50e-07 FRA20B
8 1.71e-06 FRA2H
6 1.53e-04 FRA7G
5 0.001 FRA11D FRA13A
4 0.007 FRA1G
3 0.037 FRA1E FRA3C FRA5E FRA18A FRAXB
2 0.142 FRA1D FRA3B FRA7H FRA14C FRA16C
5% 13 1.48e-10 FRA22B
11 1.98e-08 FRA1C FRA2H
10 2.02e-07 FRA20B
9 1.87e-06 FRA13A
8 1.56e-05 FRA7G FRA11D
7 1.15e-04 FRA18A
6 7.48e-04 FRA3C
5 0.004 FRA1G
4 0.019 FRA1E FRA5E FRA6E FRAXB
3 0.071 FRA1D
2 0.198 FRA3B FRA5D FRA7H FRA14C FRA16C
10% 14 4.89e-10 FRA1C FRA22B
12 4.23e-08 FRA20B
11 3.50e-07 FRA2H FRA18A
10 2.66e-06 FRA11D
9 1.83e-05 FRA1G FRA7G FRA13A
7 6.27e-04 FRA3C
6 0.003 FRA1E FRA5E
5 0.013 FRA6E FRA14C FRAXB
4 0.043 FRA1D FRAXC
3 0.119 FRA3B FRA16C
2 0.247 FRA5D 7p14 FRA7B FRA7F FRA7H 14q21
FRA16D
Fragile sites with degree higher than 2 are reported at each significance level α. Probabilities of fragile sites having observed degrees in the random 
model are reported as well.Page 6 of 18
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logical content of the network by means of the Gene
Ontology annotation scheme.
We proceed in two steps.
First, we consider the previously outlined connected com-
ponents and we explicitly list all the genes included in
them. At this point, each connected component is associ-
ated with a set of genes, collected together only by virtue
of their membership to fragile sites with similar expres-
sion profile (see Methods for details).
Second, we analyse each of these sets of genes separately,
looking for shared biological functions, according the
Gene Ontology vocabulary (see Methods section for
details) to identify genes that are more likely to be func-
tionally related than expected by chance.
To this end, a Gene Ontology filter is applied to each con-
nected component of the network. By filtering the content
of genes at correlated fragile sites we find that clustered
fragile sites are overall enriched in fourteen GO terms. For
the discussion herein we select GO terms which turned
out stably enriched at each significance level, after correc-
tion for multiple test, and are not biased by positional
constraints of genes annotated to such terms (see detailed
discussion in the Methods section). The eight GO terms
obtained in this way are: cytokine activity, hematopoie-
tin/interferon-class (D200-domain) cytokine receptor,
interferon-alpha/beta receptor binding, response to virus,
extracellular space, carboxylesterase activity, serine este-
rase activity and xenobiotic metabolism.
Finally, we manually integrate the knowledge get by Gene
Ontology with information made available from the
Kyoto Encyclopedia of Genes and Genomes (KEGG) path-
ways database website [39] and the GeneCards database
website [40].
Table 4: Comparison between clustering coefficients for the 
whole real network and for the Erdos-Renyi model at each 
significance level α.
α C Erdos-Renyi estimate
1% 0.349 0.007
5% 0.327 0.009
10% 0.380 0.013
Table 3: Fragile site's betweenness and degree measures at each significance level α.
Fragile site Betweenness Degree Betweenness Degree Betweenness Degree
α = 1% α = 5% α = 10%
FRA1C 0.121 11 0.055 11 0.170 14
FRA22B 0.103 11 0.104 13 0.076 14
FRA20B 0.078 9 0.030 10 0.060 12
FRA2H 0.086 8 0.089 11 0.082 11
FRA7G 0.058 6 0.077 8 0.038 9
FRA11D 0.004 5 0.011 8 0.080 10
FRA13A 0.004 5 0.025 9 0.028 9
FRA1G 0.004 4 0.011 5 0.135 9
FRA1E 0.000 3 0.000 4 0.103 6
FRA3C 0.002 3 0.052 6 0.028 7
FRA5E 0.000 3 0.000 4 0.115 6
FRA18A 0.053 3 0.114 7 0.170 11
FRAXB 0.005 3 0.004 4 0.005 5
FRA1D 0.000 2 0.001 3 0.003 4
FRA3B 0.013 2 0.011 2 0.017 3
FRA7H 0.013 2 0.011 2 0.000 2
FRA14C 0.020 2 0.016 2 0.120 5
FRA16C 0.020 2 0.016 2 0.088 3
FRA6E _ _ 0.000 4 0.003 5
FRA5D _ _ 0.004 2 0.001 2
FRAXC _ _ _ _ 0.000 4
7p14 _ _ _ _ 0.001 2
FRA7B _ _ _ _ 0.064 2
FRA7F _ _ _ _ 0.000 2
14q21 _ _ _ _ 0.058 2
FRA16D _ _ _ _ 0.043 2Page 7 of 18
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overrepresented in fragile sites
We perform the GO analysis for each connected compo-
nent at the three different significance levels. GO terms
that turned out to be overrepresented for at least one sig-
nificance level α are listed in Tab 6. The full sets of genes
annotated to each GO term are provided in the supple-
mentary materials [see Additional files 1, 2, 3, 4, 5]. The
following analysis refers to the α = 1% case unless other-
wise specified. We examine GO terms separately.
The GO term 'cytokine activity' represents one of the most
comprehensive GO functions including 21 genes which
grow up to 30 at α = 10%. Notably at the lowest signifi-
cance level genes annotated to 'cytokine activity' are local-
ized on fragile sites of A1 and B1 as well. For example
16q22.1 (band of FRA16C) harbours a cluster of chemok-
ine-like factor genes including CKLF, CKLF2, CKLF3 and
CKLFSF4; erythropoietin EPO, located at 7q22 (FRA7F), is
a member of the EPO/TPO family and encodes a secreted,
glycosylated cytokine provided with antiapoptotic func-
tions in several tissue types; FAM3D, a member of a
cytokine-like gene family [16], maps to 3p14.2 (FRA3B).
This observation confirms that the functionality described
by the GO term 'cytokine activity' is a common feature of
fragile sites of both connected components.
A number of genes, which share strictly related functions
and belong to the same protein family, are organized in
the genome in very close proximity. Fifteen interferon-α,
β,ε family's genes, producing antiviral and antiprolifera-
tive responses in cells, map to a narrow locus spanning
364kb at 9p21.3 (FRA9C). Leukaemia inhibitor factor
(LIF), which is a cytokine that induces macrophage differ-
entiation and chemotaxis in immune cells, and oncosta-
tin-M (OSM), cytokine encoding a growth regulator
which inhibits the proliferation of a number of tumour
cell lines, belong to the interleukin-6 family and are 16kb
apart at 22q12.2 (FRA22B).
Other genes map to independent loci. For example
thrombopoietin (THPO) at 3q27 (FRA3C), ligand for the
product of myeloproliferative leukemia virus oncogene
MPL, is a megakaryopoietic regulator. The FKBP-associ-
ated protein encoded by GLMN, mapped to 1p22
(FRA1D), has a role in the control of the immune
response and an antigrowth function and interacts with
the proto-oncogene MET [17].
This set of genes is significantly annotated also to two
descendants of the upper-level term 'cytokine activity' in
the GO graph: 'hematopoietin/interferon class-cytokine recep-
tor binding' (17 annotated genes) and 'interferon-alpha/beta
receptor binding' (8 annotated genes, partially coinciding
with the previous ones). Similarly the full interferon-α/β
family's genes are responsible for GO process 'response to
virus' being above the threshold.
The subontology 'cellular component' refers to the place
where a gene product is active. Therefore it is not a sur-
prise the overrepresentation, albeit at a less significant
level, of the GO term 'extracellular space'. Out of 31 anno-
tated genes for this GO term, 21 are annotated to the GO
term 'cytokine activity'. Ten genes specifically annotated
to the term 'extracellular space' map to eight fragile sites.
The products of genes related to 'extracellular space' mainly
act in processes such as cell-matrix interaction, degrada-
tion of matrix components, growth regulation and apop-
tosis. They are metalloprotesases (such as PLA2G3 at
22q12.2 and CLCA3 at 1p22) and serine proteases (such
as PLG at 6q26) and protease activators.
Let us mention a few GO terms that specifically character-
ize the connected component B1: 'xenobiotic metabolism'
and 'serine esterase activity'.
'Xenobiotic metabolism' seems to fit well with the notion
that fragile sites are sensitive to cancerogenic agents and
that they are involved in cancers induced by the exposi-
tion to these agents. Indeed, the cytochrome P450 (CYP)
genes at FRA7F are known to be involved in the metabo-
lism of exogenous cancerogenic agents in cancer tissues
[18]. As for the GO function 'serine esterase activity', let us
stress that the expression of a serine esterase gene is
Table 5: Comparison between community organization at α = 10% and connected component organization at α = 5%.
cluster organization at α = 5% :
A5 FRA1C FRA1D FRA1E FRA1G FRA2D FRA2H FRA3C FRA5D FRA5E FRA6E 7p14 FRA7G FRA9C
FRA10F FRA11D FRA13A FRA18A FRA20B FRA22B FRAXB FRAXC
B5 FRA3B FRA7F FRA7H FRA14C FRA16C FRA16D
C5 14q21 18p11
community organization at α = 10% :
com. no 1 FRA1C FRA1D FRA1E FRA1G 1q43 FRA2D FRA2H FRA3C FRA5D FRA5E FRA6E 7p14 FRA7B
FRA7G FRA9C FRA10F FRA11D FRA13A 14q21 18p11 FRA18A FRA20B FRA22B FRAXB FRAXC
com. no 2 FRA3B FRA7F FRA7H FRA14C FRA16C FRA16D
Communities identified at α = 10% appear as connected components at more stringent significance levels. The two communities at α = 10% 
coincide respectively with A5 and B5 at α = 5% except for C5 which is enclosed in the larger community. C5's fragile sites are highlighted by italic font 
typing.Page 8 of 18
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genes mapped to fragile sites of both connected compo-
nents turn out to be involved in environmental informa-
tion processing, albeit in distinct forms.
A detailed description of the specific pathways in which
genes annotated to significant GO terms are engaged is
provided in Tab 7.
To improve our knowledge of the relationship between
fragile sites and gene function, we examined the literature
looking for genes belonging to the correlated fragile sites
that are involved in some of the functions reported above,
even if not yet annotated for them. We found that very
recently the FHIT gene, containing the hot spot fragility
regions of FRA3B, has been shown to be involved in
inflammatory response; it directly inhibits the activation
of Prostaglandin E2, a key agent in inflammation, and by
this way it suppresses cancer cells proliferation [20]. At
FRA16D the WWOX gene has an essential role in the cel-
lular susceptibility to TNF-mediated apoptosis [21]. In the
same site PLCG2 gene maps, encoding a phospholipase C
that is a crucial enzyme in transmembrane signaling,
involved in the activation of a variety of growth factor
receptors and immune system receptors.
Together these findings show that many genes sharing the
membership to fragile sites with correlated expression
participate to common pathways, even if often with a
poorly understood role; this supports the hypothesis that
fragile sites expression is linked to a coordinated regula-
tion of expression of the fragile site associated genes.
To further characterize the functional meaning of the
genes identified by GO analysis, we analyse their possible
involvement in cancer. Tab 8 reports the full list of such
genes along with references to the sources from which we
gather information: the GeneCards database, the Atlas of
Genetics and Cytogenetics in Oncology and Haematology
database and recent papers available on PubMed data-
base. They are involved prevalently in haematological
tumours, such as leukemias, but also in breast, lung,
colon, prostate carcinomas and others. Thus, having a role
in cancer is a largely shared feature for these genes. Most
of them (such as PLG, EPO and PBEF1) exhibit broad
expression in the remodelling of the tissues surrounding
tumour cells and in the metastasis formation. For a
number of genes annotated to GO terms a co-localisation
with approved cancer genes occurs; this is the case for
FAM3D, located 900 kb distal from FHIT gene, with no
intervening genes, included by FRA3B and strictly linked
to TU3A (protein DRR1- Down-regulated in renal cell car-
cinoma 1). Moreover INFE1 is located 350 kb distal from
the MTAP, CDKN2A and CDKN2B tumour genes, still
with no intervening genes, CKLF and CKLF1-4 are located
in a cluster strictly linked to CDH5 (VE-cadherin tumour
gene). In this respect it is interesting to note that the afore-
mentioned genes are not evolutionary related paralogs.
Therefore the regional proximity seems to have a preva-
lent functional origin due to the need of a coordinated
gene expression.
Functional information is embedded in network topology
Since the co-expression network exhibits a large degree of
clustering the most natural examples of subgraphs to
Table 6: Functional characterization of fragile sites' connected components.
GO id GO term description Cluster -Log10 (p value)
α = 1% α = 5% α = 10%
GO:0005126 hematopoietin/interferon-class A1, A5, ABC10 15.090 15.408 11.807
(D200-domain) cytokine receptor A1, A5, ABC10
GO:0005132 interferon-alpha/beta receptor binding A1, A5, ABC10 12.394 11.902 9.704
GO:0009615 response to virus A1, A5, ABC10 11.857 10.889 6.811
GO:0005125 cytokine activity A1, A5, ABC10 6.252 5.843 4.919
GO:0005615 extracellular space A1, A5 5.390 4.627 < threshold
GO:0042272 nuclear RNA export factor complex A1, A5 4.713 4.538 < threshold
GO:0005515 protein binding A1 4.698 < threshold < threshold
GO:0008320 protein carrier activity ABC10 < threshold < threshold 4.645
GO:0004091 carboxylesterase activity B1, B5 7.133 7.133 _
GO:0004759 serine esterase activity B1, B5 7.133 7.133 _
GO:0006805 xenobiotic metabolism B1, B5 4.038 4.038 _
GO:0003700 transcription factor activity D10 _ _ 5.853
GO:0030528 transcription regulator activity D10 _ _ 4.758
GO:0003676 nucleic acid binding D10 _ _ 4.149
Overrepresented GO terms are reported along with their Gene Ontology identifiers, full descriptions, enriched connected component(s) for those 
GO terms and negative logarithm of their hypergeometric p-values.Page 9 of 18
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Table 7: KEGG pathways for genes annotated to overrepresented fragile sites.
Signal transduction:
MAPK signaling pathway Notch signaling pathway Wnt signaling pathway Calcium signaling pathway TGF-beta signaling pathway
PLA2G3 MAP3K13 JAG1 DVL3 SENP2 TCF7 DVL3 PDE1A SMAD5
Jak-STAT signaling pathway:
IFNA1 IFNA2 IFNA4 IFNA5 IFNA6 IFNA8 IFNA10 IFNA14 IFNA17 IFNA21 IFNB1 IFNK IFNW1 LIF OSM
EPO L12RB2
Signaling molecules and interactions:
ECM-receptor interaction Cell adhesion molecules (CAMs) Neuroactive ligand-receptor interaction
LAMC2 LAMC1 ITGAV ITGAV VCAM1 NEGR1 SST
Cytokine-cytokine receptor interaction:
IFNA1 IFNA2 IFNA4 IFNA5 IFNA6 IFNA8 IFNA10 IFNA14 IFNA17 IFNA21 IFNB1 IFNK IFNW1 LIF OSM
EPO TNFSF4 TNFSF18 L12RB2 MET
Immune system:
Natural killer cell-mediated cytotoxicity Leukocyte transendothelial migration Complement-coagulation cascades
IFNA1 IFNA2 IFNA4 IFNA5 IFNA6 IFNA8 NCF2 VCAM1 PLG SERPINC1 SERPINE1 KNG1
Toll-like receptor signaling pathway T/B cell receptor signaling pathway
IFNA1 IFNA2 IFNA4 IFNA5 IFNA6 IFNA8 IFNA10 IFNA14 IFNA17 IFNA21 IFNB1 BCL10
Cell motility and comunication:
Focal adhesion Adherens junction Tight junctin Regulation of actin cytoskeleton
TNR LAMC2 MET LAMC1 ITGAV MET INADL ITGAV NCKAP1 LIMK2
Cell growth and death:
cell cycle Apoptosis
CDC7 CDKN2A FASLG
Genetic information processing:
SNARE interactions in vesicular transport Basal transcription factors Ribosome RNA 
polymerase
Proteasom
e
SNAP25 STX6 TAF1L GTF2B RPL5 POLR2H NBEA
Lipid metabolism: Nucleotide metabolism: Xenobiotic metabolism: Glycan metabolim:
Glycerophospholipid metabolism Purine Pyramidin
e
by cytochrome P450 Glycosphingolipid 
metabolism
DBT PLA2G3 ACHE PDE1A POLR2H POLR2H CYP3A43 SMPD3
GO annotated genes are associated with their specific KEGG pathways. KEGG pathways are assembled based on the pathways' map that the KEGG database itself provides.
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)Table 8: Candidate fragile genes in tumours.
Hugo ids Gene description Fra. site Involvement in cancer
Notes References
GLMN glomulin, FKBP associated protein FRA1D familial glomangioma GCd
CLCA3 chloride channel, calcium activated FRA1D strictly linked to CLCA2, tumor suppressor gene for breast cancer Oncogene 2004 (19): 1471-80
EVI-5 EVI-5 homolog FRA1D Cell 2006 Jan 27; 124(2): 367-80
TNFSF4 TNF(ligand) superfamily, member 4 FRA1G leukemia T-cell, neoplasms AGCOH, GCd
TNFSF18 TNF(ligand) superfamily, member 18 FRA1G neoplasms AGCOH
TNR tenascin R FRA1G neoplasms AGCOH
ANGPTL1 Angiopoietin-related protein 1 precursor FRA1G neoplasms Cancer Cell 2004 Nov; 6(5):507-16
ITGAV CD51 antigen FRA2H neoplasm metastasis, colon, breast and pancreatic carcinoma Cancer Metastasis Rev 2003 Mar;22(1):103-15
FAM3D family with sequence similarity 3, member D FRA3B located 900 kb, with no intervening genes, distal from FHIT gene
THPO thrombopoietin FRA3C myeloproliferative disorders AGCOH, GCd
ADIPOQ adiponectin, C1Q and collagen domain containing FRA3C myeloblastic leukemia Br J Cancer 2006 Jan 16; 94(1):156-60
AHSG alpha-2-HS-glycoprotein FRA3C liver carcinoma GCd
BCL6 B-cell CLL/lymphoma 6 FRA3C lymphoma b-cell, lymphoma non-hodgkins, burkitt lymphoma Oncogene 2006 Jul 3
PLG plasminogen precursor FRA6E neoplasm metastasis, neoplasms vascular tissue J Cell Biochem 2005 Oct; 96(2):242-61
HOXA5 homeo box A5 7p15.2 breast carcinoma J Biol Chem 2000 Aug ; 275(34):26551-5
HOXA7,9 homeo box A7, A9 7p15.2 myeloid leukemia Leuk Res 2000 Oct; 24(10): 849-55
EPO erythropoietin FRA7F myelodyplastic syndromes AGCOH, GCd
AZGP1 alpha-2-glycoprotein 1, zinc FRA7F cancer of breast, prostate (GCd) AGCOH
PBEF1 pre-B-cell colony enhancing factor 1 FRA7F myeloid leukemia Leukemia 2005 Jun; 19(6): 998-1004
CAV-1,-2 caveolin 1, caveolin 2 FRA7G carcinoma of colon, adenocarcinoma, ovarian epithelial carcinoma Genomics 2003 Feb; 81(2):105-7
MET HGF receptor FRA7G gastric carcinoma, neoplasm metastasis, carcinoma renal cell Oncogene 2006 Jan 19; 25(3):409-18
INFB1 interferon beta 1 FRA9C neoplasms, melanoma AGCOH, GCd
IFNE1 interferon epsilon 1 FRA9C located 350 kb distal from MTAP, CDKN2A and CGKN2B tumor genes
IFNA1 interpheron alpha 1 FRA9C leukemia AGCOH, GCd
IFNA2 interpheron alpha 2 FRA9C myeloid leukemia, renal cell cancer GCd, TGD
SMPD3 sphingomyelin phosphodiesterase 3 FRA16C strictly linked to CDH3 (P-cadherin tumour gene)
CKLF chemokine-like factor FRA16C strictly linked to CDH5 (P-cadherin tumour gene)
CES2 Carboxylesterase 2 precursor FRA16C malignant neoplasms, carcinoma of colon Neoplasia 2005 Apr;7(4): 407-16
NQO1 NAD(P)H dehydrogenase, quinone 1 FRA16C carcinoma of colon, malignant neoplasm of lung, cancer of bladder Clin Cancer Res 2005 Dec; 11(24):8866-71
LIF leukemia inhibitory factor FRA22B leukemia, myeloma, neuroepitelioma, stricltly linked to HORMAD2 AGCOH, TGD
OSM oncostatin M FRA22B leukemia, myeloma, kaposi sarcoma, melanoma, plasmacitoma AGCOH, TGD
TCN2 transcobalamin II, macrocytic anemia FRA22B colon adenocarcinoma GCd
SEC14L2 SEC14-like 2 FRA22B neoplasms Cancer Res 2005 Nov 1; 65(21):9807-16
We report genes localized at the observed fragile sites which are assessed to play a role in tumour development in public databases or PubMed articles. Abbreviations for cited databases: AGCOH, Atlas of 
Genetics and Cytogenetics in Oncology and Haematology; TGD, Tumor Gene Database; GCd, Genecards database.
BMC Bioinformatics 2006, 7:413 http://www.biomedcentral.com/1471-2105/7/413study are triangles. Even though triangles are the simplest
substructures, they clearly indicate departures from ran-
domness and should point out future attempts to under-
stand instability at fragile sites.
Here we confine ourselves to showing, for example, that
triangles, which are the tightest ways to connect three
nodes, seem to reflect acquired knowledge. We choose, to
this end, a triangle which appears at the highest threshold
and is significantly annotated to all the GO terms found
overrepresented in the connected component A1. It
includes FRA7G, FRA3C and FRA22B. Interestingly two
candidate tumour suppressor genes CAV-1 and CAV-2
localize at FRA7G. They modulate cell cycle progression
through several cascades such as the inhibition of the
phosphatidylinositol 3-kinase (PI3-kinase)/Akt survival
pathway and the control of the Ras-p42/44 MAP kinase
cascade.
FRA22B harbours a family of lipid-binding proteins
including SEC14L2,-3,-4 which are homolog to the toco-
pherol-associated protein (TAP). Note that TAP exerts its
tumour suppressor function via down-regulation of PI3-
kinase/Akt signaling.
The full list of triangles at α = 1% is reported in the sup-
plementary materials [see Additional file 6].
Conclusion
Common fragile sites appear as gaps and breaks at non-
random loci on metaphase chromosomes. They are gener-
ally stable in somatic cells and inducible in cells cultured
under conditions of replicative stress. Several investiga-
tions have pointed out a direct correlation between chro-
mosomal fragility and DNA instability in various cancer
cases. Common fragile sites are hierarchical in their rela-
tive frequency of expression with FRA3B being most fre-
quently observed.
Correlated patterns of expression among a few fragile sites
have been recently observed by analysing a distinctive
sample of subjects, exposed to radiation and affected by
cancer reported in [13]. We are thereupon prompted to
clarify whether correlated breakage should be a generally
shared feature of fragile site expression. In our opinion
complex networks formalism provides the ideal tool to
answer this question. Fragile sites are described as nodes
of a network where nodes are joined in pairs if the corre-
lation in their patterns of expression is statistically signif-
icant. We focus on three robust measures of a network's
topology: clustering coefficient, division in connected
components and communities. In this respect, the most
surprising result is the existence of a large connected com-
ponent at the highest threshold along with the conserva-
tion of a well-defined sub-structure organization at each
of the significance levels set in the analysis. The computa-
tional method we propose supports aforementioned
results and extends their validity. Indeed we show that
correlated expression involves a growing number of frag-
ile sites (depending on the significance of correlation)
independently from carcinogenic exposure. This general
feature of fragile sites supports the hypothesis that they
serve a function. Assuming that network topology should
reflect underlying cellular mechanisms, we explore the
functional content of highly interconnected fragile sites
by means of the Gene Ontology vocabulary.
The functional characterization through GO of genes
located at connected fragile sites clearly highlights that a
great proportion of genes with significant annotated terms
are involved in innate and adaptive immune responses
and in particular in pathways characteristic of activated T
lymphocytes. This is of special interest, since the expressed
fragile sites in the present work have been detected in acti-
vated lymphocytes.
From these findings we propose that correlated breakage
at fragile sites may originate in proliferating lymphocytes
from a co-regulated modified expression of fragile genes;
in this view the genes identified by GO analysis may be
new fragile genes; chromatin changes and DNA replica-
tion alteration at or near these genes would be produced
by cellular processes connected with their co-regulation
performed through still unknown mechanisms. This is
supported by the observation that a number of the ana-
lysed cytokine-related genes show actual functional inter-
actions in lymphocytes or other cell types. For example
OSM and LIF, that have common biologic activities, are
stimulated by CSF2.
Interestingly, an emerging view on immune response is
that programmed gene expression is achieved by means of
epigenetic mechanisms tied to the structure of chromatin;
in particular epigenetic effects organize the ability of sig-
nal transduction pathways to generate a set of functionally
characterized cell progeny [22].
Epigenetic changes at fragile genes associated with highly
expressed fragile sites, such as FHIT and WWOX, have
been characterized in a number of tumours [23] and sug-
gested to be associated with expression of fragility [24].
Thus, epigenetic mechanisms responsible of coordinated
regulation of different loci may be involved in the chro-
matin alterations leading to chromosome fragility; these
alterations could become permanent in cells that under-
take a tumorigenic process. A surprising high proportion
of the genes identified at correlated fragile sites are impli-
cated in cancer. This finding agrees with the ancient
hypothesis of a general relationship between fragile sites
and cancer. It is supported by the detection at the charac-Page 12 of 18
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pressor genes such as the proapoptotic genes FHIT at
FRA3B and Wwox at FRA16D and others.
According to a recent proposal breakage at fragile sites
may be protective against cancer [25,11]. Such a protec-
tive role would be mediated by breaks formed in conse-
quence of aberrant replication at fragile sequences, known
to be difficult to replicate; breaks would represent a signa-
ture of replication stress and would activate the DNA
damage checkpoints leading to cell-cycle arrest or apopto-
sis to ensure genomic integrity. This proposal is supported
by the evidence that DNA damage response is activated
early in the tumorigenesis and that in this phase loss of
heterozigosity occurs preferentially at fragile sites, as pos-
sible consequence of stalled replication forks [12].
On the basis of our results on fragile site network we pro-
pose to extend it by including that replication stress at
fragile sequences is coupled with a modified expression of
the associated fragile genes. More precisely, we believe
that fragile sequences, sensitive to replication stress, are
not located by chance within or near fragile genes, but
participate together with genes to the mechanism that reg-
ulate the cellular response to DNA damage. This proposal
fits for a number of known genes mapping at highly
expressed fragile sites, such as FHIT at FRA3B, Wwox at
FRA16D, CAV1 and CAV2 at FRA7G and others, that have
a function in cell proliferation control and apoptosis. We
may ask to what extent such a proposal fits also with the
genes identified in our analysis, prevalently related to the
immune response. In particular could these genes have
the above described role in preventing genome instabil-
ity? Could their response be significant for non-lym-
phocyte cell types that are also enabled to express
chromosome fragility? Similarly to the known fragile
genes, for a number of genes here identified a function in
cell cycle control has been described.
However also other genes participating specifically in
immune response may be involved in cancer related proc-
esses; indeed a link between the immune response and
processes that regulate genome integrity has been very
recently suggested by the evidence that genotoxic stress
and stalled DNA replication up-regulate some stimulatory
receptors of the innate immune system such as NKG2D
receptor [26]. Thus, it has been suggested that DNA dam-
age response, besides arresting cell cycle, enhancing DNA
repair or triggering apoptosis may participate in alerting
the immune system to the presence of potentially danger-
ous cells [27]. Of great interest, according to a very recent
study, FHIT gene is involved in inflammatory response by
inhibiting synthesis of Prostaglandin E2, a key agent in
inflammation [20]; this finding clearly defines a function
in immunity for the major fragile gene and thus strongly
supports our hypothesis that regulation mechanisms of
fragile genes expression could be implied in fragility.
This complex relationship needs to be tested experimen-
tally. Nevertheless the candidate fragile genes identified in
our study could be investigated as actors in DNA damage
response, associated with carcinogenesis and involved in
loss of function in primary steps of tumour development.
Methods
Cytogenetic analysis
Data on breakage events at aphidicolin-sensitive fragile
sites have been obtained in three independent analyses
carried out on peripheral blood lymphocytes to compare
fragile sites expression in unexposed subjects, healthy sub-
jects and in subjects exposed to environmental carcino-
gens, such as radiations and pesticides [28,29,13]. All
analyses have been carried out by using identical cell cul-
ture procedures; chromosome breakage was detected by
two experienced cytogenetists sharing appointed criteria;
this allows reach results with high reproducibility, verified
by repeated samplings.
Chromosomes were stained with the standard GTG band-
ing technique (400 band resolution). Band localization
was assigned according to the Mitelman Database of
Chromosome Aberrations in Cancer ISCN (1995) [30].
For each subject 100 metaphases are scored for gaps,
breaks and rearrangements on coded slides; for subjects
exposed to radiation (showing very high breakage) 50
metaphases are analysed.
Our original dataset consists of the expression profiles of
343 chromosomal bands measured on a sample of 60
subjects. To test the nonrandomness of breakage at a given
chromosomal band we adopt the algorithm described in
[15] under the proportional probability assumption. This
model assumes that the probability of a random break at
a region is proportional to the range width. Basically, to
determine whether a chromosomal region is a fragile site
or not, an iterative procedure tests the region with the
highest observed standardized breakage number. If such a
region is accepted as a fragile site then the procedure goes
on to the next iteration leaving out this region. The algo-
rithm stops when it gets a subset of regions for which the
test is not able to reject the hypothesis of random break-
age.
After such analysis, we end up with a dataset of 116 chro-
mosomal bands, so that the raw data on fragile site expres-
sion can be embedded in a matrix M [116] [60] whose mij
element represents the absolute number of breakage
events (i.e. total gaps, beaks or rearrrangements) that
affect the fragile site i in the subject j. We provide thisPage 13 of 18
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7].
Subjects and cell culture
Overall, individual frequencies of breakage have been
documented for sixty subjects. This sample includes 21
healthy subjects without exposure to environmental
mutagens or carcinogens, 18 healthy subjects exposed to
pesticides, 11 subjects exposed to radiation and free from
any sign of disease, and 10 subjects exposed to radiation
and affected by papillary thyroid carcinoma, not submit-
ted to pharmacological treatments. For all subjects smok-
ing, alcohol consumption and medications have been
excluded; all were Caucasian. Informed consent was
obtained from each subject prior to initiation of the study.
Peripheral blood cultures were established from all indi-
viduals using a total 0.3 ml of whole blood, added to 4.7
ml of Ham's F10 medium, supplemented with 1.5% phy-
tohemoagglutinin, 10% fetal calf serum, and antibiotics.
The cultures were incubated at 37°C for 72 hours; aphidi-
colin (final concentration 0.4 μM) was added for the last
26 hours of culture, according to the standard protocol for
common fragile site expression. Colcemid (0.05 μg/ml)
was added 90 minutes before cell harvesting and fixing.
Chromosome preparations were set up according to
standard protocols.
Co-expression analysis
Calculation of Spearman's correlation
We evaluate the correlation between pairs of fragile sites
(i.e. between the rows of the expression matrix defined
above) using the non-parametric Spearman correlation
coefficient. The choice of this type of correlation function
(based on rank ordering) is due to the fact that in this way
we do not need any assumption about the distribution
followed by the entries of the expression matrix defined
above. Another reason which led us to choose this rank-
based type of correlation is that, due to its intrinsic robust-
ness, it allows to eliminate possible bias in the data due to
the inhomogeneity in the data sample. In this way we may
neglect the fact that the data are obtained combining four
different classes of subjects.
The Spearman rank-order correlation coefficient [31] is
defined as follows:
Here N is the total number of subjects, Ri is the rank of xi
among the other x's, Si is the rank of yi among the other y's
(  and  are the means of the ranks).
The significance of a nonzero value of rs is tested by com-
puting
which is distributed approximately as Student's distribu-
tion with N - 2 degrees of freedom. The comparison
between the experimental and theoretical distributions is
shown in Figure 4.
To sort out the co-expressed pairs of fragile sites that
mainly cause such a difference between data and model
we set several significance levels α = 1%, α = 5% and α =
10%. A correlation coefficient is evaluated as significant
only if it satisfies to the constraint t > t(1-α) where t(1-α) is t
at which the Student's cumulative density function respec-
tively accounts for 99%(t(1-α) = 5.172), 95%(t(1-α) = 4.726)
and 90%(t(1-α) = 4.529). In so doing, we perform a multi-
ple hypothesis correction based on a naive Bonferroni
test. This procedure let us operate a tight control on false
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a function of M, α' = α/M where  is
the number of correlation coefficients. This correction
guarantees that the probability of having one or more
false positives is no greater than α. Bonferroni corrected
significance levels become respectivelyα' ≈10-6, α' ≈7·10-
6, α' ≈10-5. Therefore, at the three significance levels, we
retain only Spearman's correlation coefficients whose
probability values are less than α'.
A nice feature of our results is that they seem to be largely
independent from the type of correlation function used to
obtain them. We evaluated, as a test, the same correlations
also using the Kendall function (another well known
standard non-parametric test) finding essentially the same
results.
These co-expression data can be usefully represented as a
network in which nodes stand for fragile sites and links
between couples of fragile sites are drawn if such fragile
sites exhibit a significant Spearman's correlation coeffi-
cient in the sense we've just defined.
Connected components reconstruction
We extract connected components of the networks previ-
ously constructed by using the standard Hoshen-Kopel-
man algorithm [32]. This algorithm is one of the most
efficient tools to find the connected components in an
arbitrary undirected graph.
Comparison with the random graph hypothesis
The Erdos-Renyi random graph is the simplest possible
model for a network. It depends on two parameters only:
the number of vertices n and the probability p of connect-
ing two vertices with an edge. Actually this model
describes not a single graph but an ensemble (in the sense
of statistical mechanics) of graphs in which a graph with
exactly n vertices and m edges appears with probability pm
(1 - p)M-m where  is the number of pairs of
vertices of the graph (and hence the maximum possible
number of edges). The most important feature of the
model is the presence at a particular value of p of a phase
transition called percolation transition in which suddenly
a giant connected component appears in the graph. This
transition occurs exactly at z = 1 (where z is the mean
degree of the graph and is given by z = p(n-1)).
It is easy to see that the three thresholds discussed in the
text correspond to networks with a link densities p =
0.0069, p = 0.0094 and p = 0.0126 respectively i.e. to a
mean expected degree z = 0.79, z = 1.08 and z = 1.45.
While for the lowest threshold the mean degree is in the
percolating phase and so it is not surprising that we find a
giant connected component in the graph, the mean degree
for the highest threshold z = 0.79 is far below the percola-
tion threshold, thus the fact that also in this case a large
connected component appears is a highly non trivial
result.
Another important feature of random graphs is that, due
to their simplicity, it's rather easy to evaluate a number of
important graph theoretical quantities. In particular in
our analysis we used the probability of a vertex having a
degree k  and the mean
clustering coefficient which (for an undirected graph) is
defined as:
 where 
where ejk denotes an edge between vertices vk and vj which
are among the nearest neighbours of the vertex vi (degree
Ki).
Community structure of the network
Algorithm
To display the community structure of the network we
apply the agglomerative hierarchical clustering algorithm
proposed by Newman [33]. The starting state has each ver-
tex standing isolated. The joining of communities
together in pairs is chosen so that it results in the greatest
increase (or smallest decrease) in the modularity coeffi-
cient Q (see next section for the exact definition). The best
partition of the network in communities corresponds to
the maximal value of Q.
Validation of the community structure
The so called "modularity coefficient" is defined as
 where eij is the fraction of edges in the
network that connect vertices of the community i with
those of the community j. Roughly speaking Q measures
the fraction of edges which lie within the community
minus the expected value for the same quantity in a ran-
dom graph, thus for a random graph Q = 0 while larger
values of Q indicate a significant departure from a ran-
dom distribution of the edges. It is interesting to observe
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thresholds Q is compatible with zero, thus indicating that
no substructure is present in these components. On the
contrary at the lowest threshold Q is definitely larger than
0 thus indicating that the large connected component that
we find at this threshold is actually the combination of
two separate subcomponents (which almost exactly coin-
cide with those that we find at the highest thresholds).
Functional characterization of connected components by 
Gene Ontology (GO) filter
Cytogenetic definition of fragile sites is adopted except
when a more precise identification of boundaries could be
found in the literature [see Additional file 8]. The NCBI
database for gene specific information offers positional
information on all recognized common fragile sites. The
first step is the construction of the sets of genes located at
fragile sites belonging to the connected components that
are detected at each significance level. We produce a map-
ping of the genes to their corresponding fragile sites by the
means of the data mining Biomart tool provided by the
Ensembl [34] database [41] (Ensemblv36).
We perform a bioinformatics analysis using the Gene
Ontology functional annotation scheme [38], version
3.1191) to investigate potential correlations between the
function, biological role and cellular location of the pro-
tein products of genes and their location at fragile sites.
We filter the set of genes by each of the three main subon-
tologies (biological process, molecular function and cellular
component) separately. We always consider a gene anno-
tated to a certain GO term and to all its ascendants in the
GO hierarchy. For every GO term the number of associ-
ated genes within the set is calculated. We perform an
exact Fisher's test to check whether the term appears in the
set significantly more often than expected by chance.
Indeed the Fisher's test gives the probability P of obtain-
ing an equal or greater number of genes annotated to each
term in a set made of the same number of genes but
selected at random from the full list of annotated genes in
the human genome. For a given GO term t let K(t) be the
total number of genes annotated to it in the genome and
k(t) the number of genes annotated to it in the set. If J and
j denote the number of genes in the human genome and
in the set respectively, such probability is given by the
right tail of the hypergeometric distribution:
where
If P is statistically significant, then we can postulate the
existence of a correlation between the overrepresentation
of the term and the functional characterization of the gene
set.
Note that, as we perform the Fisher's test for above 19000
GO terms, adjustment of estimates of statistical signifi-
cance for multiple testing are needed. In agreement with
our previous experience [35,36] where we deal with this
issue, we adopt P = 10-4 as the threshold on the Fisher's
test P-values.
Genomic localization effects on Gene Ontology outcomes
Chromosomal localization of genes annotated to statisti-
cally significant GO terms is worthy of caution because it
might somehow bias the importance of GO outcomes at
two levels.
First, the occurrence of a p-value above the threshold of
acceptance may sometimes reflect the presence of clusters
of functional families at a few fragile sites. Therefore the
extension of this functional feature to the full connected
component might be a forced interpretation of the actual
outcomes. In our wok our decision to accept or not such
cases depends on whether or not a GO term adds to a gen-
eralized functional characterization of the connected
component. Let us mention two examples. Both 'response
to virus' and 'interferon-α/β receptor binding' ought their
acceptable p-values to the co-localization of several mem-
bers of the interferon-α/β family at 9p21.3. However we
report these GO terms because they agree with a number
of other outcomes as described in Results and Discussion.
Authors' contributions
AR: implementation of the algorithms, data analysis and
participation in the project design.
DC: Gene-Ontology analysis of the data.
AP: participation in the discussion on biological signifi-
cance of results.
MC: project design and supervision of the computational
part.
IS: project design and supervision.
All the authors contributed to the manuscript writing,
read and approved the final version.
P J K t j k t F J K t j h
h k t
j K t
( , ( ), , ( )) ( , ( ), , )
( )
min( , ( ))
=
=
∑
F J K j h
K
h
J K
j h
J
j
, , ,( ) =
⎛
⎝⎜
⎞
⎠⎟
−
−
⎛
⎝⎜
⎞
⎠⎟
⎛
⎝⎜
⎞
⎠⎟Page 16 of 18
(page number not for citation purposes)
BMC Bioinformatics 2006, 7:413 http://www.biomedcentral.com/1471-2105/7/413Additional material
Acknowledgements
The authors thank Leonardo Cocchi for expert technical assistance and 
Ferdinando Di Cunto, Paolo Provero and Tiziana Venesio for useful discus-
sions. This work is partially supported by the Fund for Investiments of Basic 
Research (FIRB) from the Italian Ministry of the University and Scientific 
Research, No. RBNE03B8KK-006.
References
1. Glover TW: Common fragile sites.  Cancer Lett 232(1):4-12.
Review 2006 Jan 28
2. Corbin S, Neilly ME, Espinosa R 3, Davis EM, McKeithan TW, Le Beau
MM: Identification of unstable sequences within the common
fragile site at 3p14.2: implications for the mechanism of dele-
tions within fragile histidine triad gene/common fragile site
at 3p14.2 in tumors.  Cancer Res 62(12):3477-84. 2002 Jun 15
3. Matsuyama A, Shiraishi T, Trapasso F, Kuroki T, Alder H, Mori M,
Huebner K, Croce CM: Fragile site orthologs FHIT/FRA3B and
Fhit/Fra14A2: evolutionarily conserved but highly recombi-
nogenic.  Proc Natl Acad Sci USA 100(25):14988-93. 2003 Dec 9
4. Schwartz M, Zlotorynski E, Kerem B: The molecular basis of com-
mon and rare fragile sites.  Cancer Lett 232(1):13-26. Review
2006 Jan 28
5. Cha RS, Kleckner N: ATR homolog Mec1 promotes fork pro-
gression, thus averting breaks in replication slow zones.  Sci-
ence 2002, 297:602-606.
6. Casper AM, Nghiem P, Arlt MF, Glover TW: ATR regulates fragile
sites stability.  Cell 2002, 111:779-789.
7. Nyberg KA, Michelson RJ, Putnam CW, Weinert TA: Toward main-
taining the genome DNA damage and replication check-
points.  Annu Rev Genet 2002, 36:617-656.
8. Cimprich KA: Fragile sites: breaking up over a slowdown.  Curr
Biol 2003, 13(6):R231-3.
Additional file 1
Gene Ontology characterization of the connected component A1 at α = 
1%. Gene Ontology characterization of the connected component A1 when 
the significance level for fragile site correlation is set to 1%. Significantly 
over-represented GO words are associated the full set of annotated genes. 
Genes' identifiers provided by the Hugo Gene Nomenclature Committee 
(Hugo ids) and genes' localization in fragile sites are reported.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-7-413-S1.pdf]
Additional file 2
Gene Ontology characterization of the connected component B1 at α = 1% 
and α = 5%. Gene Ontology characterization of the connected component 
B1 when the significance level for fragile site correlation is set to 1% and 
to 5%. Significantly over-represented GO words are associated the full set 
of annotated genes. Genes' identifiers provided by the Hugo Gene Nomen-
clature Committee and genes' localizations in fragile sites are reported.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-7-413-S2.pdf]
Additional file 3
Gene Ontology characterization of the connected component A5 at α = 
5%. Gene Ontology characterization of the connected component A5 when 
the significance level for fragile site correlation is set to 5%. Significantly 
over-represented GO words are associated the full set of annotated genes. 
Genes' identifiers provided by the Hugo Gene Nomenclature Committee 
and genes' localizations in fragile sites are reported.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-7-413-S3.pdf]
Additional file 4
Gene Ontology characterization of the connected component ABC10at α 
= 10%. Gene Ontology characterization of the connected component 
ABC10 when the significance level for fragile site correlation is set to 10%. 
Significantly over-represented GO words are associated the full set of 
annotated genes. Genes' identifiers provided by the Hugo Gene Nomen-
clature Committee and genes' localizations in fragile sites are reported.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-7-413-S4.pdf]
Additional file 5
Gene Ontology characterization of the connected component D10 at α = 
10%. Gene Ontology characterization of the connected component D10 
when the significance level for fragile site correlation is set to 10%. Sig-
nificantly over-represented GO words are associated the full set of anno-
tated genes. Genes' identifiers provided by the Hugo Gene Nomenclature 
Committee and genes' localizations in fragile sites are reported.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-7-413-S5.pdf]
Additional file 6
Full list of triangles detected at α = 1%. The full list of triangles detectable 
at the significance level for fragile site correlated expression set to α = 1%.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-7-413-S6.pdf]
Additional file 7
Fragile sites expression matrix. Data on fragile sites expression are embed-
ded in a matrix M [116] [60] whose mij element represents the absolute 
number of breakage events that affect the fragile site i in the subject j 
(each entry of the matrix refers to 100 metaphases). The rows in the 
matrix correspond to the fragile sites and the columns to the different sub-
jects.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-7-413-S7.txt]
Additional file 8
Cytogenetic position of fragile sites. Cytogenetic position of fragile sites is 
reported in the first column; when cytogenetic regions where fragility has 
been observed include annotated fragile sites, we specify annotated fragile 
sites along with their genomic position. Fragile sites' genomic lengths and 
overall breakage occurrences are provided as well.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2105-7-413-S8.pdf]Page 17 of 18
(page number not for citation purposes)
BMC Bioinformatics 2006, 7:413 http://www.biomedcentral.com/1471-2105/7/413Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
9. Iliopoulos D, Guler G, Han SY, Druck T, Ottey M, McCorkell KA,
Huebner K: Roles of FHIT and WWOX fragile genes in cancer
.  Cancer Lett 232(1):27-36. 2006 Jan 28
10. Miller CT, Lin L, Casper AM, Lim J, Thomas DG, Orringer MB, Chang
AC, Chambers AF, Giordano TJ, Glover TW, Beer DG: Genomic
amplification of MET with boundaries within fragile site
FRA7G and upregulation of MET signaling pathways in
esophageal adenocarcinoma.  Oncogene 25(3):409-18. 2006 Jan
19
11. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg
P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J:
DNA damage response as a candidate anti-cancer barrier in
early human tumorigenesis.  Nature 434(7035):864-70. 2005
Apr 14
12. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A,
Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, Kletsas
D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD: Activation of the
DNA damage checkpoint and genomic instability in human
precancerous lesions.  Nature 434(7035):907-13. 2005 Apr 14
13. Sbrana I, Veroni F, Nieri M, Puliti A, Barale R: Chromosomal fragile
sites FRA3B and FRA16D show correlated expression and
association with failure of apoptosis in lymphocites from
patients with thyroid cancer.  Genes Chromosomes Cancer 2006,
45(5):429-36.
14. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM,
Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-
Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M,
Rubin GM, Sherlock G: Gene ontology: tool for the unification
of biology. The Gene Ontology Consortium.  Nat Genet 2000,
25(1):25-9.
15. Hou CD, Chiang J, Tai JJ: Testing the nonrandomness of chro-
mosomal breakpoints using highest observed breakages.
Hum Genet 1999, 104:350-355.
16. Zhu Y, Xu G, Patel A, McLaughlin MM, Silverman C, Knecht K,
Sweitzer S, Li X, McDonnell P, Mirabile R, Zimmerman D, Boyce R,
Tierney LA, Hu E, Livi GP, Wolf B, Abdel-Meguid SS, Rose GD,
Aurora R, Hensley P, Briggs M, Young PR: Cloning, expression,
and initial characterization of a novel cytokine-like gene fam-
ily.  Genomics 2002, 80(2):144-50.
17. Krummrei U, Baulieu EE, Chambraud B: The FKBP-associated
protein FAP48 is an antiproliferative molecule and a player
in T cell activation that increases IL2 synthesis.  Proc Natl Acad
Sci U S A 100(5):2444-9. 2003 Mar 4
18. Oyama T, Kagawa N, Kunugita N, kitagawa K, Ogawa M, Yamaguchi
T, Suzuki R, Kinaga T, Yashima Y, Ozaki S, Isse T, Kim YD, Kim H,
Kawamoto T: Expression of cytochrome P450 in tumor tissues
and its association with cancer development.  Front Biosci 9:
1967-76. Review 2004 May 1
19. Caputo A, Fahey D, Lloyd C, Vozab R, McCairns E, Rowe PB: Struc-
ture and differential mechanisms of regulation of expression
of a serine esterase gene in activated human T lymphocytes
.  J Biol Chem 263(13):6363-9. 1988 May 5
20. Mimori K, Ishii H, Nagahara H, Sudo T, Yamashita K, Inoue H, Barnard
GF, Mori M: FHIT is up-regulated by inflammatory stimuli and
inhibits prostaglandin E2-mediated cancer progression.  Can-
cer Res 66(5):2683-90. 2006 Mar 1
21. Chang NS, Doherty J, Ensign A, Schultz L, Hsu LJ, Hong Q: WOX1
is essential for tumor necrosis factor-, UV light-, stau-
rosporine-, and p53-mediatedcell death, and its tyrosine 33-
phosphorylated form binds and stabilizes serine 46-phospho-
rylated p53.  J Biol Chem 280(52):43100-8. 2005 Dec 30
22. Reiner SL: Epigenetic control in the immune response.  Hum
Mol Genet 14(Spec No 1):R41-6. 2005 Apr 15
23. Fabbri M, Iliopoulos D, Trapasso F, Aqeilam RI, Cimmino A, Zanesi N,
Yendamuri S, Han SY, Amadori D, Huebner K, Croce CM: WWOX
gene restoration prevents lung cancer growth in vitro and in
vivo.  Proc Natl Acad Sci USA 102(43):15611-6. 2005 Oct 25
24. Ishii H, Vecchione A, Furukawa Y, Sutheesophon K, Han SY, Druck T,
Kuroki T, Trapasso F, Nishimura M, Saito Y, Ozawa K, Croce CM,
Huebner K, Furukawa Y: Expression of FRA16D/WWOX and
FRA3B/FHIT genes in hematopoietic malignancies.  Mol Can-
cer Res 2003, 1(13):940-7.
25. O'Keefe LV, Richards RI: Common chromosomal fragile sites
and cancer: focus on FRA16D.  Cancer Lett 232(1):37-47. 2006
Jan 28
26. Gasser S, Orsulic S, Brown EJ, Raulet DH: The DNA damage path-
way regulates innate immune system ligands of the NKG2D
receptor.  Nature 436(7054):1186-90. 2005 Aug 25
27. Hoglund P: DNA damage and tumor surveillance: one trigger
for two pathways.  Sci STKE 2006, 2006(317):pe2.
28. Musio A, Sbrana I: Aphidicolin-sensitive specific common frag-
ile sites: a biomarker of exposure to pesticides.  Environ Mol
Mutagen 1997, 29(3):250-5.
29. Sbrana I, Musio A: Enhanced expression of common fragile site
with occupational exposure to pesticides.  Cancer Genet
Cytogenet 82(2):123-7. 1995 Jul 15
30. ISCN: An International System for Human Cytogenetic
Nomenclature.  Edited by: Mitelman F. S.Karger, Basel; 1995. 
31. Press W, Vetterling W, Teukolsky S, Flannery B: Numerical Reci-
pes in C. The art of scientific computing.  Second.
32. Hoshen J, Kopelman R: Percolation and cluster distribution.
Cluster multiple labeling technique and critical concentra-
tion algorithm.  Phys Rev B 1976, 14:3438-3445.
33. MEJ Newman: Fast algorithm for detecting community struc-
ture in networks.  Phys Review E 2004, 69:066133.
34. Birney E, Andrews D, Caccamo M, Chen Y, Clarke L, Coates G, Cox
T, Cunningham F, Curwen V, Cutts T, Down T, Durbin R, Fernandez-
Suarez XM, Flicek P, Graf S, Hammond M, Herrero J, Howe K, Iyer V,
Jekosch K, Kahari A, Kasprzyk A, Keefe D, Kokocinski F, Kulesha E,
London D, Longden I, Melsopp C, Meidl P, Overduin B, Parker A,
Proctor G, Prlic A, Rae M, Rios D, Redmond S, Schuster M, Sealy I,
Searle S, Severin J, Slater G, Smedley D, Smith J, Stabenau A, Stalker
J, Trevanion S, Ureta-Vidal A, Vogel J, White S, Woodwark C, Hub-
bard TJ: Ensembl 2006.  Nucleic Acids Res :D556-61. 2006 Jan 1
35. Corà D, Di Cunto F, Provero P, Silengo L, Caselle M: Computa-
tional identification of transcription factor binding sites by
functional analysis of sets of genes sharing overrepresented
upstream motifs.  BMC Bioinformatics 5:57. 2004 May 11
36. Corà D, Hermann C, Dieterich C, Di Cunto F, Provero P, Caselle M:
Ab initio identification of putative human transcription fac-
tor binding sites by comparative genomics.  BMC Bioinformatics
6(1):110. 2005 May 2
37. The National Center for Biotechnology Information   [http://
www.ncbi.nlm.nih.gov/]
38. The Gene Ontology Project   [http://www.geneontology.org/]
39. The Kyoto Encyclopedia of Genes and Genomes (KEGG)
[http://www.genome.ad.jp/kegg/]
40. The GeneCards Database   [http://www.genecards.org/]
41. The Ensembl Genome Browser   [http://www.ensembl.org]Page 18 of 18
(page number not for citation purposes)
